News & Perspective

Sep 16, 2019

Sep 16, 2019
HHS Secretary Azar Ebola

US officials end visit to DRC Ebola region; cases rise to 3,129

US officials said other outbreak indicators such as deaths in the community need to improve before they feel more confident about the recent drop in cases.

Sep 10, 2019

Sep 10, 2019
Trip to DR Congo Ebola front lines

Azar, Redfield among US officials heading to DRC to assess Ebola

Cases have grown to 3,084, including 2,070 deaths.

Aug 12, 2019

Aug 12, 2019
Alima cube

Ebola outbreak treatment trial narrowed to two promising drugs

Officials hope the promising treatment findings encourage more patients to seek lifesaving treatment.

Aug 01, 2019

Aug 01, 2019
DRC PPE

Two new cases in Goma as DRC Ebola outbreak reaches 1-year mark

In other developments, the WHO said Beni is still the main hot spot and that the pace of new infections hasn't changed much.

Apr 03, 2019

Apr 03, 2019
Community Ebola representatives in DR Congo

DRC Ebola total hits 1,100; study targets secondary spread

Admission to an Ebola treatment unit was tied to a 38% drop in secondary cases.

Jan 29, 2019

Jan 29, 2019
DR Congo women

Katwa remains outbreak hot spot as Ebola cases reach 743

Four of the 7 new cases were reported in Katwa, the latest outbreak hot spot.

Dec 13, 2018

Dec 13, 2018
Ebola baby

Officials note 10 new Ebola cases as youngest patient recovers

Also, the NIAID has reached an agreement to license an experimental treatment.

Oct 30, 2018

Oct 30, 2018
ebola vaccine

Ebola total hits 276 as lasting effect noted for 3 vaccines

Immune response lasted 2.5 years for the vaccines, the longest yet in ongoing studies of Ebola immunization.

Aug 16, 2018

Aug 16, 2018
vaccine research

CEPI announces new collaboration and funding for Lassa vaccine

The announcement comes as Nigeria is experiencing its largest outbreak, with 481 confirmed cases reported as of last week, 133 of them fatal.

Oct 11, 2017

Oct 11, 2017
Ebola vaccine study

Liberia trial finds Ebola vaccines yield year-long immune response

A trial at the end of Liberia's Ebola outbreak shows 2 candidate vaccines posed no major safety concerns and triggered immune responses that lasted at least a year.

Pages

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»